keyword
MENU ▼
Read by QxMD icon Read
search

Prednisone side effects

keyword
https://www.readbyqxmd.com/read/28800947/-from-pathogenesis-of-giant-cell-arteritis-to-new-therapeutic-targets
#1
M Samson, B Bonnotte
Giant cell arteritis (GCA) is the most common vasculitis in adults. GCA is a granulomatous large-vessel vasculitis involving the aorta and its major branches in people>50 years. Glucocorticoids (GC) remain the cornerstone of GCA treatment. Prednisone is usually started at 0.7 or 1mg/kg/day depending on the occurrence of ischemic complications. Then, GC are progressively tapered and stopped after a mean duration of 18 months. GC are very efficient but relapses often occur during their tapering. Moreover, GC-related side effects are very common during this long term GC therapy...
August 8, 2017: La Revue de Médecine Interne
https://www.readbyqxmd.com/read/28792625/the-effect-of-full-dose-composite-tissue-allotransplantation-immunosuppression-on-allograft-motor-nerve-regeneration-in-a-rat-sciatic-nerve-model
#2
Jong Pil Kim, Caroline A Hundepool, Patricia F Friedrich, Steven L Moran, Allen T Bishop, Alexander Y Shin
BACKGROUND: The purpose of this study was to identify which triple immunosuppressive protocols, currently used for vascularized composite allotransplantation in the clinic, will have the best effect on motor function recovery following nerve allograft reconstruction. METHODS: Eighty-eight Lewis rats underwent a 1-cm sciatic nerve allograft transplantation and skin graft from 44 Brown-Norway rats. Group I received 0.9% isotonic saline (control); Group II, 2 mg/kg FK506; Group III, 1 mg/kg FK506 with 15 mg/kg mycophenolate mofetil (MMF); and Group IV, 2 mg/kg FK506 with 30 mg/kg MMF and prednisone...
August 9, 2017: Microsurgery
https://www.readbyqxmd.com/read/28791802/a-26-week-feasibility-study-comparing-the-efficacy-and-safety-of-modified-release-prednisone-with-immediate-release-prednisolone-in-newly-diagnosed-cases-of-giant-cell-arteritis
#3
Charles Raine, Philip P Stapleton, Dimos Merinopoulos, Win Win Maw, Katerina Achilleos, Dawn Gayford, Sarah Mapplebeck, Craig Mackerness, Paul Schofield, Bhaskar Dasgupta
OBJECTIVE: A feasibility study to assess efficacy and safety of modified release (MR) prednisone (Lodotra™) compared to immediate release (IR) prednisolone in patients with newly diagnosed giant cell arteritis (GCA). METHODS: Twelve patients with new diagnosis of GCA were initially treated with high-dose prednisolone (40-60 mg) daily for 4 weeks and then randomized to two open arms to continue tapering steroid treatment with either standard IR prednisolone or MR prednisone...
August 9, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/28772029/ace-inhibitor-associated-intestinal-angioedema-in-orthotopic-heart-transplantation
#4
Dushyanth Srinivasan, Garth W Strohbehn, Thomas Cascino
Angiotensin-converting enzyme inhibitor induced angioedema commonly involves the head and neck area. We report a case of angiotensin-converting enzyme inhibitor induced intestinal angioedema in a heart transplant recipient on mTOR immunosuppression. A 36-year-old Caucasian woman with history of heart transplantation on sirolimus, tacrolimus and prednisone presented to the Emergency Department with abdominal pain, one day following lisinopril initiation. A computer tomography scan demonstrated diffuse bowel wall thickening consistent with pancolitis and edema...
August 2017: ESC Heart Failure
https://www.readbyqxmd.com/read/28766491/a-case-of-severe-nephrotoxicity-associated-with-long-term-dietary-supplement-use
#5
Farrukh M Koraishy, Gilbert W Moeckel, David S Geller
Dietary supplements are widely used for their perceived health benefits without side effects and hence have minimal regulation. However, they have been associated with various toxicities including kidney disease. We report a 65-year-old male who had very heavy daily intake of dietary supplements for 3 years. He presented with acute kidney injury and nephrotic-range proteinuria. The renal biopsy showed acute tubular necrosis with vacuolization, acute interstitial nephritis, and secondary membranous nephropathy, consistent with an non-steroidal anti-inflammatory drug (NSAID)-like nephropathy...
August 2, 2017: Clinical Nephrology
https://www.readbyqxmd.com/read/28763304/chronic-inflammatory-demyelinating-polyneuropathy
#6
Richard A Lewis
PURPOSE OF REVIEW: As a syndrome with typical and atypical cases, chronic inflammatory demyelinating polyneuropathy (CIDP) has been a difficult disorder to diagnose and treat. The pathophysiologic basis for CIDP has not been established, contributing to the challenges in dealing with these patients. However, as one of only a handful of treatable peripheral neuropathies, there has been a tendency to diagnose CIDP to attempt a therapeutic intervention. We are also aware that there has also been overtreatment of some patients...
July 29, 2017: Current Opinion in Neurology
https://www.readbyqxmd.com/read/28750787/high-dose-filgrastim-treatment-of-nonregenerative-pancytopenia-associated-with-chronic-canine-ehrlichiosis
#7
Mauricio Palacios, Rafael Arteaga, Gustavo Calvo
OBJECTIVE: To report the management and outcome of a dog with canine monocytic ehrlichiosis and nonregenerative pancytopenia, with high doses of filgrastim. CASE DESCRIPTION: An 8-year-old male, mixed-breed dog, weighing 5.6kg, presented with a 1-month history of hyporexia, adynamia, and a weight loss of approximately 1kg. The general condition of the dog was observed to be poor as follows: lethargy, tachycardia, marked pallor of the mucous membranes, petechiae on the abdomen, hepatosplenomegaly, and cervical lymphadenopathy...
March 2017: Topics in Companion Animal Medicine
https://www.readbyqxmd.com/read/28749817/prednisolone-and-prednisone-pharmacokinetics-in-pediatric-renal-transplant-recipients-a-prospective-study
#8
Ragnhild Heier Skauby, Anna Bjerre, Ingjerd Sæves, Nils Tore Vethe, Sara Bremer, Anja Svarstad, Stein Bergan
BACKGROUND: Prednisolone is a standard component of immunosuppressive protocols in renal transplantation (Tx) and despite standardized treatment regimens, adverse side effects are still frequent. The aim of this study was to characterize the pharmacokinetics of prednisolone and prednisone in pediatric renal transplant recipients in the first 52 weeks post Tx, to describe the relationship between prednisolone and prednisone, and to investigate a possible relationship between the development of new onset diabetes after Tx (NODAT) and glucocorticoid exposure...
July 26, 2017: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/28745999/trial-of-tocilizumab-in-giant-cell-arteritis
#9
RANDOMIZED CONTROLLED TRIAL
John H Stone, Katie Tuckwell, Sophie Dimonaco, Micki Klearman, Martin Aringer, Daniel Blockmans, Elisabeth Brouwer, Maria C Cid, Bhaskar Dasgupta, Juergen Rech, Carlo Salvarani, Georg Schett, Hendrik Schulze-Koops, Robert Spiera, Sebastian H Unizony, Neil Collinson
BACKGROUND: Giant-cell arteritis commonly relapses when glucocorticoids are tapered, and the prolonged use of glucocorticoids is associated with side effects. The effect of the interleukin-6 receptor alpha inhibitor tocilizumab on the rates of relapse during glucocorticoid tapering was studied in patients with giant-cell arteritis. METHODS: In this 1-year trial, we randomly assigned 251 patients, in a 2:1:1:1 ratio, to receive subcutaneous tocilizumab (at a dose of 162 mg) weekly or every other week, combined with a 26-week prednisone taper, or placebo combined with a prednisone taper over a period of either 26 weeks or 52 weeks...
July 27, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28686693/ivermectin-treatment-of-loa-loa-hyper-microfilaraemic-baboons-papio-anubis-assessment-of-microfilarial-load-reduction-haematological-and-biochemical-parameters-and-histopathological-changes-following-treatment
#10
Samuel Wanji, Ebanga-Echi J Eyong, Nicholas Tendongfor, Che J Ngwa, Elive N Esuka, Arnaud J Kengne-Ouafo, Fabrice R Datchoua-Poutcheu, Peter Enyong, Dalen Agnew, Rob R Eversole, Adrian Hopkins, Charles D Mackenzie
BACKGROUND: Individuals with high intensity of Loa loa are at risk of developing serious adverse events (SAEs) post treatment with ivermectin. These SAEs have remained unclear and a programmatic impediment to the advancement of community directed treatment with ivermectin. The pathogenesis of these SAEs following ivermectin has never been investigated experimentally. The Loa/baboon (Papio anubis) model can be used to investigate the pathogenesis of Loa-associated encephalopathy following ivermectin treatment in humans...
July 2017: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/28612627/pharmacokinetic-drug-evaluation-of-budesonide-in-the-treatment-of-crohn-s-disease
#11
REVIEW
Lukasz Kwapisz, Vipul Jairath, Reena Khanna, Brian Feagan
Crohn's disease (CD) is a chronic inflammatory disorder that commonly affects the terminal ileum and proximal colon. Although systemic corticosteroids such as prednisone and methylprednisolone are widely used for treatment of CD, these agents have a high incidence of adverse drug reactions due to off-target effects. Budesonide is a locally acting corticosteroid with enhanced formulation properties that offer a superior therapeutic index in comparison to conventional members of the class. Areas covered: This review focuses on budesonide for the treatment of CD...
July 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/28612375/outcome-of-adolescents-and-young-adults-compared-to-children-with-hodgkin-lymphoma-treated-with-response-based-chemotherapy-on-pediatric-protocols-a-children-s-oncology-group-report
#12
Karen S Fernández, Cindy L Schwartz, Lu Chen, Louis S Constine, Allen Chauvenet, Pedro A de Alarcón
PURPOSE: We evaluated the outcome of children (<15 years) versus that of adolescents and young adults (AYA; 15-≤ 21 years) treated for Hodgkin lymphoma (HL) in two Pediatric Oncology Group/Children's Oncology Group clinical trials, P9425 and P9426, that used dose-dense, response-based chemotherapy and reduced dose radiotherapy. PATIENTS AND METHODS: Subjects 21 years or younger with HL were eligible for these studies. Subjects with low-risk (stages IA, IIA, and IIIA1) without large mediastinal adenopathy biopsy-proven HL, eligible for P9426, were treated with two to four 28-day cycles of doxorubicin, bleomycin, vincristine, and etoposide (ABVE) chemotherapy and 25...
June 14, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28596831/ofatumumab-associated-acute-pneumonitis-not-new-but-still-the-first-case
#13
Alice Bonanni, Enrica Bertelli, Chiara Panicucci, Matteo D'Alessandro, Andrea Moscatelli, Elisabetta Lampugnani, Oliviero Sacco, Gian Michele Magnano, Pietro Ravani, Gian Marco Ghiggeri
Ofatumumab is an anti-CD20 humanized monoclonal antibody utilized in the treatment of several clinical conditions resistant to other treatments. In spite there was a general expectation that ofatumumab was less toxic compared to rituximab, side effects have been reported that resemble those of its anti-CD20 chimeric precursor. Here, we describe the first case of Ofatumumab associate lung injury occurring in a 14-year-old boy affected by nephrotic syndrome dependent to prednisone plus cyclosporine A who had been treated with the dose of drug utilized in nephrotic syndrome (1500 mg/173 m(2))...
February 2017: Pharmacology Research & Perspectives
https://www.readbyqxmd.com/read/28564619/repeated-pulses-of-methyl-prednisolone-with-reduced-doses-of-prednisone-improve-the-outcome-of-class-iii-iv-and-v-lupus-nephritis-an-observational-comparative-study-of-the-lupus-cruces-and-lupus-bordeaux-cohorts
#14
REVIEW
Guillermo Ruiz-Irastorza, Amaia Ugarte, Cecile Saint-Pastou Terrier, Estibaliz Lazaro, Amalur Iza, Lionel Couzi, Ramon Saenz, Christophe Richez, Sabrina Porta, Patrick Blanco
OBJECTIVE: To compare the clinical course of patients with class III, IV and V lupus nephritis (LN) treated at Hospital Universitario Cruces (CC) and at Bordeaux University Hospital (BC). METHODS: The Lupus-Cruces nephritis protocol combines pulses of 125mg of methyl-prednisolone with each fortnightly pulse of cyclophosphamide and prednisone ≤30mg/day with tapering over 12-14weeks until 2.5-5mg/day. The BC followed international lupus nephritis guidelines, combining high-dose prednisone and either mycophenolate mofetil or cyclophosphamide, followed by maintenance therapy with low dose prednisone and immunosuppressive drugs...
May 28, 2017: Autoimmunity Reviews
https://www.readbyqxmd.com/read/28562168/the-efficacy-and-safety-of-tacrolimus-monotherapy-in-adult-onset-nephrotic-syndrome-caused-by-idiopathic-membranous-nephropathy
#15
Qian Liang, Heng Li, Xishao Xie, Fangzhi Qu, Xiayu Li, Jianghua Chen
INTRODUCTION: The purpose of the study is to evaluate the efficiency and safety of tacrolimus (TAC) monotherapy in the treatment of nephrotic idiopathic membranous nephropathy (IMN) compared with the protocol of cyclophosphamide (CTX) combined with corticosteroids. METHODS: In total, 58 patients with nephrotic syndrome and biopsy-proven IMN were included in this study. 30 patients received TAC monotherapy with an initial dose of 0.05-0.1 mg/kg/day. 28 patients received transvenous CTX at a dose of 0...
November 2017: Renal Failure
https://www.readbyqxmd.com/read/28557602/systemic-steroid-sparing-effect-of-intravitreal-dexamethasone-implant-in-chronic-noninfectious-uveitic-macular-edema
#16
Claudia Fabiani, Antonio Vitale, Giacomo Emmi, Giuseppe Lopalco, Lorenzo Vannozzi, Daniela Bacherini, Silvana Guerriero, Rosa Anna Favale, Fiorella Fusco, Rossella Franceschini, Bruno Frediani, Florenzo Iannone, Mauro Galeazzi, Gian Marco Tosi, Luca Cantarini
PURPOSE: To evaluate the effectiveness and the systemic corticosteroid sparing effect of a single intravitreal dexamethasone (DEX) implant in patients with chronic noninfectious uveitic macular edema (UME). METHODS: Data from 22 eyes treated with DEX implant for UME related to systemic or ocular-confined noninfectious diseases were retrospectively analyzed. RESULTS: The mean systemic prednisone (or equivalent) dosage significantly decreased at 3- and 6-month follow-up evaluations compared to baseline (P = 0...
May 30, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28556421/gastrointestinal-disorders-after-immunosuppression-an-experimental-model-to-evaluate-the-influence-of-monotherapy-on-motility-parameters
#17
Denize Jussara Rupolo Dall'Agnol, Luciana Aparecida Corá, Maria do Carmo Borges Teixeira, Maysa Bruno de Lima, Loyane Almeida Gama, José Ricardo de Arruda Miranda, Madileine Francely Américo
What is the central question of this study? The aim was to propose an animal model for investigating the effects of immunosuppressive monotherapy on gastrointestinal motility using a non-invasive biomagnetic technique. What is main finding and its importance? In our experimental study, immunosuppressive drugs currently in use accelerated gastric emptying whilst increasing the frequency and amplitude of gastric contractions after treatment, except for Mycophenolate and azathioprine. Alternating current biosusceptometry is a useful tool to evaluate side-effects of drugs on the gastrointestinal tract, which will help in understanding the symptoms and improving clinical management of patients...
May 26, 2017: Experimental Physiology
https://www.readbyqxmd.com/read/28541603/comparison-of-first-line-chemotherapy-including-escalated-beacopp-versus-chemotherapy-including-abvd-for-people-with-early-unfavourable-or-advanced-stage-hodgkin-lymphoma
#18
REVIEW
Nicole Skoetz, Andrea Will, Ina Monsef, Corinne Brillant, Andreas Engert, Bastian von Tresckow
BACKGROUND: There are two different international standards for the treatment of early unfavourable and advanced stage Hodgkin lymphoma (HL): chemotherapy with escalated BEACOPP (bleomycin/etoposide/doxorubicin/cyclophosphamide/vincristine/procarbazine/prednisone) regimen and chemotherapy with ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) regimen. OBJECTIVES: To determine the advantages and disadvantages of chemotherapy including escalated BEACOPP compared to chemotherapy including ABVD in the treatment of early unfavourable or advanced stage HL as first-line treatment...
May 25, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28537866/eruptive-sebaceous-hyperplasia-as-a-side-effect-of-oral-tacrolimus-in-a-renal-transplant-recipient
#19
Katherine A Levandoski, Nicholas A Girardi, Manisha J Loss
Sebaceous hyperplasia, a benign proliferation ofsebaceous glands, has been well documented in organ transplant recipients treated with cyclosporine. Sebaceous hyperplasia has not been strongly associated with any other immunosuppressive medications. We report a case of eruptive sebaceous hyperplasia in a renal transplant recipient with no previous exposure to cyclosporine that was recently started on tacrolimus, mycophenolate mofetil, and prednisone. To our knowledge, this is the first report of eruptive sebaceous hyperplasia in a renal transplant recipient who was immunosuppressed with tacrolimus and had no prior exposure to cyclosporine...
May 15, 2017: Dermatology Online Journal
https://www.readbyqxmd.com/read/28534173/successful-treatment-of-patients-with-newly-diagnosed-untreated-light-chain-multiple-myeloma-with-a-combination-of-bendamustine-prednisone-and-bortezomib-bpv
#20
Hannah Tessenow, Madlen Holzvogt, Bruno Holzvogt, Marc Andrea, Simone Heyn, Thomas Schliwa, Maik Schwarz, Thomas Zehrfeld, Cornelia Becker, Christian Pfrepper, Georg Nikolaus Franke, Rainer Krahl, Madlen Jentzsch, Sabine Leiblein, Sebastian Schwind, Marius Bill, Vladan Vucinic, Thoralf Lange, Dietger Niederwieser, Wolfram Pönisch
INTRODUCTION: Patients with light chain myeloma frequently have a light chain tubular cast nephropathy, which can lead to severe renal impairment. In the present retrospective study, bortezomib was combined with other active substances like bendamustine and prednisone (BPV), in order to assess the efficacy and toxicity of the combination therapy in patients with light chain multiple myeloma. METHODS: Between September 2008 and May 2015, 25 patients with newly diagnosed light chain multiple myeloma were treated with bendamustine 60 mg/m(2) on days 1 and 2, bortezomib 1...
May 22, 2017: Journal of Cancer Research and Clinical Oncology
keyword
keyword
73309
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"